NAT1 and triple-negative breast carcinoma: The overexpression of this miRNA, miR-6744-5p promotes anoikis in both luminal A and triple negative breast cancer cell lines, and miR-6744-5p directly target NAT1 enzyme, indicating its potential in breast cancer therapeutics and prognostics.